These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

160 related articles for article (PubMed ID: 36377586)

  • 21. Glucocorticoid Dosages and Acute-Phase Reactant Levels at Giant Cell Arteritis Flare in a Randomized Trial of Tocilizumab.
    Stone JH; Tuckwell K; Dimonaco S; Klearman M; Aringer M; Blockmans D; Brouwer E; Cid MC; Dasgupta B; Rech J; Salvarani C; Schulze-Koops H; Schett G; Spiera R; Unizony SH; Collinson N
    Arthritis Rheumatol; 2019 Aug; 71(8):1329-1338. PubMed ID: 30835950
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Treatment failure in giant cell arteritis.
    Unizony SH; Bao M; Han J; Luder Y; Pavlov A; Stone JH
    Ann Rheum Dis; 2021 Nov; 80(11):1467-1474. PubMed ID: 34049857
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Outcomes during and after long-term tocilizumab treatment in patients with giant cell arteritis.
    Matza MA; Dagincourt N; Mohan SV; Pavlov A; Han J; Stone JH; Unizony SH
    RMD Open; 2023 Apr; 9(2):. PubMed ID: 37024237
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Tocilizumab monotherapy for large vessel vasculitis: results of 104-week treatment of a prospective, single-centre, open study.
    Saito S; Okuyama A; Okada Y; Shibata A; Sakai R; Kurasawa T; Kondo T; Takei H; Amano K
    Rheumatology (Oxford); 2020 Jul; 59(7):1617-1621. PubMed ID: 31665468
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Tocilizumab in refractory giant cell arteritis. Monotherapy versus combined therapy with conventional immunosuppressive drugs. Observational multicenter study of 134 patients.
    Calderón-Goercke M; Castañeda S; Aldasoro V; Villa I; Moriano C; Romero-Yuste S; Narváez J; Gómez-Arango C; Pérez-Pampín E; Melero R; Becerra-Fernández E; Revenga M; Álvarez-Rivas N; Galisteo C; Sivera F; De Miguel E; Prieto-Peña D; González-Gay MÁ; Hernández JL; Blanco R;
    Semin Arthritis Rheum; 2021 Apr; 51(2):387-394. PubMed ID: 33607384
    [TBL] [Abstract][Full Text] [Related]  

  • 26. An agent-to-agent real life comparison study of tocilizumab versus abatacept in giant cell arteritis.
    Rossi D; Cecchi I; Sciascia S; Naretto C; Alpa M; Roccatello D
    Clin Exp Rheumatol; 2021; 39 Suppl 129(2):125-128. PubMed ID: 33635228
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Tocilizumab for giant cell arteritis.
    Antonio AA; Santos RN; Abariga SA
    Cochrane Database Syst Rev; 2022 May; 5(5):CD013484. PubMed ID: 35560150
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Vision loss in patients with giant cell arteritis treated with tocilizumab.
    Amsler J; Kysela I; Tappeiner C; Seitz L; Christ L; Scholz G; Stalder O; Kollert F; Reichenbach S; Villiger PM
    Arthritis Res Ther; 2021 Mar; 23(1):92. PubMed ID: 33752737
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Effectiveness Of Tocilizumab In Aortitis And Aneurysms Associated With Giant Cell Arteritis.
    Martín-Gutiérrez A; Loricera J; Narváez J; Aldasoro V; Maiz O; Vela P; Romero-Yuste S; de Miguel E; Galíndez-Agirregoikoa E; Fernández-López JC; Ferraz-Amaro I; Sánchez-Martín J; Moya P; Campos C; López-Gutiérrez F; Castañeda S; Blanco R;
    Eur J Intern Med; 2024 Jun; ():. PubMed ID: 38908981
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Does glucocorticosteroid-resistant large-vessel vasculitis (giant cell arteritis and Takayasu arteritis) exist and how can remission be achieved? A critical review of the literature.
    Kötter I; Henes JC; Wagner AD; Loock J; Gross WL
    Clin Exp Rheumatol; 2012; 30(1 Suppl 70):S114-29. PubMed ID: 22640655
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Assessment of the efficacy and safety of tocilizumab in patients over 80 years old with giant cell arteritis.
    de Boysson H; Le Besnerais M; Blaison F; Daumas A; Jarrot PA; Perrin F; Tieulié N; Maria A; Duffau P; Gombert B; Samson M; Espitia O; Lambert M; Mékinian A; Aouba A;
    Arthritis Res Ther; 2021 May; 23(1):143. PubMed ID: 34011407
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Efficacy and safety of tocilizumab in giant cell arteritis: a single centre NHS experience using imaging (ultrasound and PET-CT) as a diagnostic and monitoring tool.
    Sebastian A; Kayani A; Prieto-Pena D; Tomelleri A; Whitlock M; Mo J; van der Geest N; Dasgupta B
    RMD Open; 2020 Nov; 6(3):. PubMed ID: 33161376
    [TBL] [Abstract][Full Text] [Related]  

  • 33. An expanded population of pathogenic regulatory T cells in giant cell arteritis is abrogated by IL-6 blockade therapy.
    Miyabe C; Miyabe Y; Strle K; Kim ND; Stone JH; Luster AD; Unizony S
    Ann Rheum Dis; 2017 May; 76(5):898-905. PubMed ID: 27927642
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Magnetic resonance angiography in giant cell arteritis: results of a randomized controlled trial of tocilizumab in giant cell arteritis.
    Reichenbach S; Adler S; Bonel H; Cullmann JL; Kuchen S; Bütikofer L; Seitz M; Villiger PM
    Rheumatology (Oxford); 2018 Jun; 57(6):982-986. PubMed ID: 29529280
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Tocilizumab for giant cell arteritis.
    Antonio AA; Santos RN; Abariga SA
    Cochrane Database Syst Rev; 2021 Aug; 8(8):CD013484. PubMed ID: 34420204
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Sustained remission after long-term biological therapy in patients with large vessel vasculitis: an analysis of ten cases.
    Vinicki JP; García-Vicuña R; Arredondo M; López-Bote JP; García-Vadillo JA; Castañeda S; Álvaro-Gracia JM
    Reumatol Clin; 2017; 13(4):210-213. PubMed ID: 27499427
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Evidence for uncoupling of clinical and 18-FDG activity of PET/CT scan improvement in tocilizumab-treated patients with large-vessel giant cell arteritis.
    Prieto Peña D; Martínez-Rodríguez I; Atienza-Mateo B; Calderón-Goercke M; Banzo I; González-Vela MC; Castañeda S; Llorca J; González-Gay MÁ; Blanco R
    Clin Exp Rheumatol; 2021; 39 Suppl 129(2):69-75. PubMed ID: 33253103
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Long-term effect of tocilizumab in patients with giant cell arteritis: open-label extension phase of the Giant Cell Arteritis Actemra (GiACTA) trial.
    Stone JH; Han J; Aringer M; Blockmans D; Brouwer E; Cid MC; Dasgupta B; Rech J; Salvarani C; Spiera R; Unizony SH; Bao M;
    Lancet Rheumatol; 2021 May; 3(5):e328-e336. PubMed ID: 38279390
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Pathophysiology of large vessel vasculitis and utility of interleukin-6 inhibition therapy.
    Yoshifuji H
    Mod Rheumatol; 2019 Mar; 29(2):287-293. PubMed ID: 30427262
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Tocilizumab for induction and maintenance of remission in giant cell arteritis: a phase 2, randomised, double-blind, placebo-controlled trial.
    Villiger PM; Adler S; Kuchen S; Wermelinger F; Dan D; Fiege V; Bütikofer L; Seitz M; Reichenbach S
    Lancet; 2016 May; 387(10031):1921-7. PubMed ID: 26952547
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.